Can I Take Lion's Mane with AOD-9604?

What AOD-9604 Does in the Body

AOD-9604 is a 15-amino-acid synthetic fragment derived from the C-terminal region of human growth hormone (amino acids 176-191), with an added tyrosine residue at the N-terminus. It was developed by Metabolic Pharmaceuticals in Australia as a candidate anti-obesity agent intended to reproduce GH's lipolytic activity without GH's effects on glucose metabolism and tissue growth.

Mechanism of Lipolysis

Preclinical work indicates the peptide acts on beta-3 adrenergic receptor signaling in adipose tissue, stimulating hormone-sensitive lipase and increasing triglyceride breakdown, according to preclinical research. In an animal study, chronic treatment with a modified GH C-terminal fragment reduced fat mass in obese mice without significantly changing food intake or lean body mass, and did not raise IGF-1 [2]. That IGF-1 finding is relevant to this article because it separates AOD-9604 from full-length GH therapy, where elevated IGF-1 is a recognized concern.

A Human Trial With Mixed Results

A later trial of an oral AOD-9604 formulation assessed safety and tolerability and reported no significant change in fasting glucose, insulin, or IGF-1 versus placebo in a small trial. The same program did not demonstrate weight loss superior to placebo, and the oral formulation was discontinued. Exact dosing and enrollment figures for that trial are not repeated here because they cannot be confirmed from the source material available for this review; a reader who needs the precise numbers should pull the primary paper directly.

How Lion's Mane Works

Lion's mane (Hericium erinaceus) is an edible medicinal mushroom with a long history of use in East Asian traditional medicine. Modern research has focused on two compound families: hericenones (fruiting body) and erinacines (mycelium), both associated with stimulating nerve growth factor (NGF) synthesis in astrocyte models [4].

NGF and Cognitive Function

A double-blind, placebo-controlled trial in Japanese adults with mild cognitive impairment found that lion's mane extract taken over 16 weeks produced significantly better scores on a standardized cognitive scale compared with placebo, with the benefit fading within weeks of stopping supplementation [5]. This trial establishes biological plausibility for NGF-related effects in humans; it says nothing about interaction with AOD-9604 or any other peptide.

Antiplatelet Properties

Laboratory research has found that a hot-water extract of Hericium erinaceus suppresses collagen-induced platelet aggregation in a dose-dependent manner [6]. The concentrations studied in vitro are well above what typical oral dosing (roughly 500 to 3,000 mg/day of extract) is expected to achieve in plasma, but individual differences in absorption mean the antiplatelet signal should not be dismissed outright, particularly for anyone already on a blood thinner.

Consumer-facing supplement safety resources generally describe lion's mane as well tolerated at standard oral doses, while flagging a theoretical bleeding-risk caution for people on anticoagulant or antiplatelet medication or using injectable therapies [7]. That is a general caution rather than a finding specific to AOD-9604.

Assessing the Interaction Risk

No published case report, pharmacovigilance signal, or clinical trial has evaluated co-administration of AOD-9604 and lion's mane. What follows is a mechanistic assessment, not a report of observed harm or observed safety.

Pharmacokinetic Considerations

AOD-9604 is given subcutaneously and is rapidly broken down by peptidases in circulation, with an estimated half-life well under an hour. Lion's mane is taken orally and its constituents are absorbed through the GI tract and metabolized hepatically. Lion's mane is not established as a meaningful inhibitor or inducer of cytochrome P450 enzymes, and the two compounds do not share a metabolic pathway or route of administration. On that basis, a pharmacokinetic interaction is unlikely.

Evidence-Status Interaction Assessment

Pharmacodynamic Considerations

Three theoretical concerns are worth naming explicitly:

1. Antiplatelet effect at injection sites. AOD-9604 is injected subcutaneously, typically into abdominal fat. If lion's mane contributes even modest systemic antiplatelet activity, injection-site bruising or slower clotting could increase. This risk would be additive with aspirin, fish oil, or other antiplatelet supplements already in use.

2. NGF and adipose tissue cross-talk. NGF receptors are expressed on adipose tissue and NGF-TrkA signaling has been linked to sympathetic innervation of fat tissue in animal imaging work [9]. Whether lion's mane's effect on NGF synthesis could modify AOD-9604's activity in either direction is speculative; no study has tested it.

3. Immune modulation overlap. Lion's mane polysaccharides have shown immune-activating effects in preclinical models [10], and AOD-9604 has been suggested to have anti-inflammatory effects in cartilage in preclinical osteoarthritis research. Whether these preclinical, tissue-specific findings translate into any meaningful interaction in humans at typical doses is unknown.

Formal endocrinology guidance on growth hormone therapy generally advises that patients disclose all supplements and unapproved treatments to their prescribing clinician, since interaction data for off-label and compounded GH-related products are limited [12]. That guidance was written for FDA-approved GH replacement therapy in diagnosed GH deficiency, a different population and product than compounded AOD-9604, so it should be read as a general disclosure principle rather than specific evidence about this combination.

AOD-9604 is not FDA-approved and is available only through compounding under Section 503A, a pathway with its own oversight requirements and limitations that differ from an approved drug.

Dose-Separation Strategy

Given the absence of a confirmed interaction alongside plausible pharmacodynamic overlap, a conservative dose-separation approach is a reasonable precaution, not a data-backed requirement.

Timing Approach Some Clinicians Use

AOD-9604 is commonly dosed once daily by subcutaneous injection, typically in the morning on an empty stomach. Lion's mane extract is usually taken once or twice daily with meals. Separating the two by at least 60 minutes is a common-sense buffer rather than a tested threshold. An example schedule:

• Morning: AOD-9604 injection (fasted, subcutaneous)
• At least 60 minutes later: lion's mane with breakfast
• Evening (optional): second lion's mane dose with dinner

When Closer Timing May Be Acceptable

If someone has taken both compounds together for several weeks without bruising, bleeding, or neurological symptoms, and a prescribing clinician has reviewed relevant labs, a shorter separation window may be reasonable. This is an individualized judgment call, not a general recommendation.

Monitoring Recommendations

Anyone combining AOD-9604 with lion's mane should track the following, especially in the first 8 weeks. These are general safety-monitoring principles for an unstudied combination, not evidence that specific problems occur.

Laboratory Monitoring

• Complete blood count (CBC) with platelet count at baseline and around 4 weeks
• Coagulation panel (PT/INR) if also taking an anticoagulant
• Fasting glucose and insulin at baseline and around 8 weeks
• IGF-1 at baseline, to confirm AOD-9604 is not producing unexpected GH-axis stimulation

Clinical Monitoring

• Injection-site bruising larger than about 2 cm or lasting more than 5 days
• Petechiae or spontaneous bruising elsewhere on the body
• Unusual bleeding from gums or nose
• New cognitive changes, positive or negative
• GI discomfort, which either compound can cause independently

What to Do If You Are Already Taking Both

There is no established danger signal for this combination, so someone already combining AOD-9604 and lion's mane without medical guidance does not need to panic.

Step-by-Step Self-Assessment

1. Review current doses. Lion's mane above roughly 3,000 mg/day of extract, or AOD-9604 above typical prescribed ranges, moves outside commonly used amounts.
2. Check for bruising at injection sites and compare with any baseline experience using AOD-9604 alone.
3. Note new GI symptoms, since lion's mane occasionally causes mild nausea or diarrhea at higher doses.
4. Tell the prescribing clinician at the next visit, with exact product names, doses, and timing.
5. Request baseline labs if none have been drawn in the past three months.

When to Stop and Seek Care

Stop one or both compounds and contact a provider for: bleeding that does not stop with standard pressure, a severe headache with cognitive changes, or signs of an allergic reaction such as rash, swelling, or difficulty breathing. Lion's mane allergy is uncommon but documented in people with mushroom sensitivities.

Special Populations

Patients on Anticoagulant or Antiplatelet Therapy

Warfarin, apixaban, rivaroxaban, clopidogrel, and even daily low-dose aspirin all increase bleeding risk. Adding lion's mane on top of any of these, alongside a subcutaneously injected peptide, layers a third factor onto bleeding risk. Anyone in this category should discuss the combination with their prescribing physician or hematologist before starting, rather than relying on general dosing guidance.

Pregnant or Breastfeeding Individuals

Neither AOD-9604 nor lion's mane has adequate human safety data in pregnancy or lactation. Both should be avoided in pregnancy and breastfeeding.

Immunocompromised Patients

Lion's mane's immune-stimulating polysaccharides could theoretically interact with autoimmune disease activity or immunosuppressive medication. People with lupus, rheumatoid arthritis, or transplant recipients on calcineurin inhibitors should consult their specialist before adding lion's mane to any peptide regimen.

The Bottom Line on This Stack

This combination sits in a gray zone common to peptide-and-supplement stacking: no evidence of harm, but also no direct evidence of safety, because no one has studied it. The pharmacokinetic interaction risk looks low, since the two compounds do not share metabolic pathways. The pharmacodynamic risk is plausible but unquantified, driven mainly by lion's mane's antiplatelet activity at AOD-9604's injection sites.

Anyone combining them should consider spacing doses by roughly an hour, get baseline labs (CBC, fasting glucose, IGF-1), and watch injection sites closely during the first month, with earlier follow-up if on a blood thinner or if any bleeding or bruising pattern changes. Because AOD-9604 remains an unapproved, compounded product with limited long-term human safety data, treat any specific numeric safety claim about this pairing, from any source, as something to verify with a prescribing clinician or pharmacist rather than take at face value.